Less Ads, More Data, More Tools Register for FREE

Pin to quick picksRockwood Strat. Regulatory News (RKW)

Share Price Information for Rockwood Strat. (RKW)

Share Price is delayed by 15 minutes
Get Live Data
316.00    3.00 (0.95%)
Bid:
316.00
Ask:
319.00
Spread: 3.00 (0.949%)
Market Cap: £179.20m
RKW Live PriceLast checked at - London Stock Exchange

Intraday Rockwood Strat. Share Chart

Trading Update

4 Oct 2023 07:00

RNS Number : 5832O
Rockwood Strategic PLC
04 October 2023
 

4 October 2023

Rockwood Strategic plc("RKW" or "the Company")

Trading Update

 

Rockwood Strategic plc (LSE: RKW) today provides an update ahead of publication of its unaudited results for the six months ended 29 September 2023 (the "Period").

 

Highlights

 

·     

Net Asset Value (NAV) Total Return in the period of -5.5% to 1851.59p/share which compares to a decline in the FTSE AIM All Share Index of -10.3% and an increase in the FTSE Small Cap (ex-ITs) Index of 2.9%. Total Shareholder Return in the Period was -2.5%.

 

·     

NAV Total Return performance in the year to 29th September 2023 of 28% which compares to the FTSE AIM All Share Index of -9.9% and the FTSE Small Cap (ex-ITs) of 8.8%. The Total Shareholder Return in the same one year period was 25.4%.

 

·     

NAV Total Return performance in the three years to 29th September 2023 of 80.3% which compares to the FTSE AIM All Share return of -24.3% and the FTSE Small Cap (ex-ITs) of 35%. The Total Shareholder Return in the same three-year period was 114%.

 

·     

No. 1 ranked fund over the last 3 years by Total Shareholder Return and Net Asset Value Total Return in the AIC UK Small Companies sector.

 

·     

At Period end the Company's shares traded at a discount of 4.1% to NAV/share, narrowing from 7.1% at the beginning of the Period. A total of 146,863 shares were successfully issued at a premium to NAV/share, growing the total number of shares issued by 5.7%.

 

·     

Net cash of £3.5m at the end of the Period, representing 7% of NAV, having reduced from 21.2% in March 2023 due to 4 new investments and increased investment in existing portfolio holdings.

 

·     

21 Period end holdings, with the top ten investments cumulatively representing 64.3% of NAV.

 

·     

Sub-division of Rockwood's shares on a ten for one basis announced separately today, with sub-division effective on 11 October 2023.

 

 

Portfolio Highlights

·     

Recommended cash offer announced for Finsbury Food Group (unrealised IRR 38.5% at Period end).

 

·     

Significant management change across a range of recent investments, as pre-identified catalysts for improved operational performance occur, including:

 

o  Mike England appointed CEO of Flowtech Fluidpower

o  Simon Goodwin and Christopher Humphrey respectively appointed CFO and NED of RM Plc

o  Iain Percival and Serena Lang respectively appointed CEO and Chair of Trifast

o  Zyllah Byng-Thorne appointed Executive Chair of M&C Saatchi

o  Charles Skinner appointed CEO of Restore

o  Stephen Welker appointed Chair of Hostmore

·     

Material special dividends, an enhanced dividend policy and significant contract wins announced by Galliford Try.

 

·     

Breakthrough contract wins announced by Filtronic Plc with the European Space Agency and a leader global provider of low earth orbit satellites, in addition to prestigious grant funding with the Ministry of Defence's Technology Exploitation Programme.

 

·     

Large increase in Trifast investment as 'springboard' holding becomes 'core'. Harwood advised funds have cumulatively increased the shareholding to 6.2%. Rockwood portfolio weighting was 8.2% of NAV at Period end.

 

·     

Bonhill delisted after returning the capital from asset sales via a tender offer.

 

·     

New 'Springboard/opportunity' holdings established at James Fisher & Sons, Filtronic and Restore.

 

 

 

Richard Staveley, Fund Manager, Harwood Capital LLP said:

 

"During a challenging period for UK smaller company equities, Rockwood's investee companies have been making a number of managerial, operational and strategic changes which we expect to catalyse significant future shareholder value creation. Rockwood's focused and engaged strategy is differentiated and we are tremendously excited about the potential from the portfolio of deeply undervalued companies, most of which have material profit recovery potential. The current gloom prevailing in UK equities unsurprisingly provides outstanding conditions for medium-term investors. We have the patience, the capital, the expertise and the drive to exploit these generationally low valuations. We warmly welcome those that have joined the register during the period, and we remain fully aligned with all shareholders to continue delivering best in class returns."

 

The latest Investor Presentation and Q3 Factsheet will be available shortly at www.rockwoodstrategic.co.uk.

Rockwood Strategic plc

Chairman

 

Noel Lamb

 

020 7264 4444

 

Harwood Capital LLP

Investment Manager

 

 

Christopher Hart

 

020 7640 3200

Singer Capital Markets Advisory LLP

 

 

 

James Maxwell

James Fischer

 

 020 7496 3000

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTNKNBBABDDCKK
Date   Source Headline
19th Nov 20247:00 amRNSInterim results
18th Nov 20244:10 pmRNSNet Asset Value(s)
18th Nov 20247:00 amRNSIssue of Equity and TVR
12th Nov 20247:00 amRNSIssue of Equity and TVR
11th Nov 20243:34 pmRNSNet Asset Value(s)
5th Nov 20247:00 amRNSIssue of Equity and TVR
4th Nov 20241:34 pmRNSNet Asset Value(s)
1st Nov 20244:22 pmRNSNet Asset Value(s)
28th Oct 20243:21 pmRNSHolding(s) in Company
28th Oct 20243:15 pmRNSNet Asset Value(s)
28th Oct 20247:00 amRNSIssue of Equity and TVR
25th Oct 20247:00 amRNSIssue of Equity
22nd Oct 20247:00 amRNSIssue of Equity and TVR
21st Oct 20244:06 pmRNSNet Asset Value(s)
14th Oct 20243:52 pmRNSNet Asset Value(s)
7th Oct 20244:47 pmRNSNet Asset Value(s)
3rd Oct 20247:00 amRNSTrading Update
1st Oct 20245:31 pmRNSNet Asset Value(s)
30th Sep 20243:51 pmRNSNet Asset Value(s)
30th Sep 20247:00 amRNSIssue of Equity
23rd Sep 20243:18 pmRNSNet Asset Value(s)
23rd Sep 20247:00 amRNSIssue of Equity and TVR
23rd Sep 20247:00 amRNSInvestor Presentation via Investor Meet Company
19th Sep 20247:00 amRNSIssue of Equity and TVR
16th Sep 20243:56 pmRNSNet Asset Value(s)
11th Sep 20247:00 amRNSIssue of Equity
10th Sep 20247:00 amRNSIssue of Equity
9th Sep 20243:50 pmRNSNet Asset Value(s)
9th Sep 20247:00 amRNSIssue of Equity
4th Sep 20247:00 amRNSIssue of Equity
2nd Sep 20243:21 pmRNSNet Asset Value(s)
27th Aug 20243:31 pmRNSNet Asset Value(s)
19th Aug 20244:35 pmRNSNet Asset Value(s)
12th Aug 20246:01 pmRNSHolding(s) in Company
12th Aug 20245:50 pmRNSNet Asset Value(s)
8th Aug 20247:00 amRNSIssue of Equity
7th Aug 20247:00 amRNSIssue of Equity
6th Aug 20247:00 amRNSIssue of Equity
5th Aug 20243:29 pmRNSNet Asset Value(s)
1st Aug 20244:08 pmRNSNet Asset Value(s)
31st Jul 20241:00 pmRNSResult of AGM
31st Jul 202412:07 pmRNSPublication of a Prospectus
30th Jul 20247:00 amRNSBlock Listing Application
29th Jul 20243:28 pmRNSNet Asset Value(s)
22nd Jul 20243:47 pmRNSNet Asset Value(s)
15th Jul 20245:00 pmRNSNet Asset Value(s)
15th Jul 20243:02 pmRNSHolding(s) in Company
15th Jul 20241:55 pmRNSHolding(s) in Company
15th Jul 20241:37 pmRNSHolding(s) in Company
15th Jul 20241:21 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.